GENE ONLINE|News &
HitGen Partners with Dorian to develop DNA-Encoded Library-Based Anti-Aging Drugs
Jin Li, Chairman & CEO of HitGen Image source: www.163.com
China-based pharmaceutical company HitGen has announced a research collaboration with Dorian Therapeutics on May 24th. Under the agreement, HitGen will receive an undisclosed upfront payment from Dorian.
HitGen, renowned for its DNA-encoded libraries (DEL) in early drug discovery and is profited by it. DEL enables the synthesis and screening of unprecedented chemicals more efficiently, and it is now available for over 1 trillion DNA-encoded compounds. The collaboration with Dorian shows HitGen’s ambition to expand its pharmaceutical business in age-related diseases.
Senoblockers – Treatments Enhancing Regenerative Capacity of Aging cells
Senoblockers are treatments for aging diseases developed by Dorian. They act on aged tissues to reactivate the generation of cells, which provide therapeutics for aging diseases like Alzheimer’s, osteoporosis, and autoimmune diseases. HitGen will apply its platform technology to those disease targets senoblockers treat for.
Previous Collaborations
On April 6th, HitGen signed a drug discovery collaboration with BioAge, a company specializing in building biobanks that identify drug targets of elderly diseases. The partnership with BioAge and Dorian has the potential for HitGen to open up markets on age-associated diseases.
“We look forward to working with Dorian to identify novel small molecule starting points from DNA-encoded libraries,” Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen said, “We will work closely with Dorian scientists to generate new lead compounds for their research programs to address unmet medical needs associated with aging.”
Related Article: AstraZeneca, Geneseeq Sign Collaborative Deal to Build Bio Center in China
Related posts:
Insilico Medicine, Taisho Partnership Sets Precedent in Drug Discovery and Development
Two Clinical-Stage Biopharmas Enter Agreement to Develop Drug for Hematologic Malignancies
Bayer’s New Anti-Tumor Drug BAY 2416964 Receives Approval for Clinical Use in China
ROSALIND Partners with Two Korean Biotechs to Expand Cancer Research in Asia
